IMV (IMV) has notable insider buying

IMV (T:IMV)

IMV Inc. (IMV) has a high amount of executive buying compared to its small-cap peers over the past three months. According to recent regulatory filings, three insiders have invested a total amount of $204,326.James Willis Hall, a Director, acquired 7,101 Common Shares on a direct ownership basis at a price of $2.304 through an exercise of warrants on June 8th, 2018. This represents a $16,361 investment into the company's shares and an account share holdings change of 14.4%.

Andrew J. Sheldon, a Director, acquired 3,500 Common Shares on a direct ownership basis at a price of $7.990 through the public market on June 8th, 2018. This represents a $27,965 investment into the company's shares and an account share holdings change of 5.9%.

Alfred Smithers, a Director, acquired 20,000 Common Shares on an indirect ownership basis for registered holder Iona Resources Holdings Limited at a price of $8.000 through the public market on June 5th, 2018. This represents a $160,000 investment into the company's shares and an account share holdings change of 36.9%.

Imv Inc, formerly known as Immunovaccine Inc is a Canada-based clinical-stage immuno oncology company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company's DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications. The DepoVax platform is used in multiple vaccine candidates, including over two-cancer vaccine candidates that have completed Phase I clinical trials. Its lead cancer vaccine, DPX- Survivac, is tested in a company-sponsored Phase II trial in lymphoma and a Phase Ib trial in ovarian cancer. Its infectious disease vaccine against respiratory syncytial virus (RSV) is in a Phase I clinical trial in Halifax, Nova Scotia.